search
Back to results

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (EXPLORE44)

Primary Purpose

Duchenne Muscular Dystrophy, Exon 44

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AOC 1044
Placebo
Sponsored by
Avidity Biosciences, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Duchenne Muscular Dystrophy focused on measuring EXPLORE44, Avidity Biosciences, Avidity, AOC 1044

Eligibility Criteria

7 Years - 55 Years (Child, Adult)MaleAccepts Healthy Volunteers

Part A: Key Inclusion Criteria: Aged 18 to 55 years, inclusive, at the time of informed consent Body mass index (BMI) of 18.5 to 32.0 kg/m2 Key Exclusion Criteria: Clinically significant abnormalities in laboratory results, ECGs, or vitals Current or recent use of prescription or nonprescription drugs Positive drug/alcohol test at Screening or Day -1 Elevated blood pressure (BP) >130/80 mmHg at Screening Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply Part B: Key Inclusion Criteria: Aged 7 to 27 years, inclusive, at the time of informed consent Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years Confirmation of DMD gene mutation amenable to exon 44 skipping Weight ≥ 23 kg Ambulatory or non-ambulatory Ambulatory participants: LVEF ≥50% and FVC≥50% Non-ambulatory participants: LVEF ≥45% and FVC≥40% PUL 2.0 entry item A ≥3 If on corticosteroids, stable dose for 30 days before screening and throughout the study Key Exclusion Criteria: Biceps brachii muscles unsuitable for biopsy Serum hemoglobin < lower limit of normal Uncontrolled hypertension or diabetes Prior treatment with any cell or gene therapy Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent Recently treated with an investigational drug History of multiple drug allergies

Sites / Locations

  • Stanford UniversityRecruiting
  • Rare Disease Research - AtlantaRecruiting
  • Worldwide Clinical Trials (Part A only)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

AOC 1044-CS1 Part A - Single Dose Levels 1-5

AOC 1044-CS1 Part A - Single Dose: Placebo

AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3

AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo

Arm Description

AOC 1044 will be administered once.

Placebo will be administered once.

AOC 1044 will be administered three times.

Placebo will be administered three times.

Outcomes

Primary Outcome Measures

Incidence of treatment-emergent adverse events (TEAEs)

Secondary Outcome Measures

Plasma pharmacokinetic (PK) parameters
Maximum plasma concentration (Cmax) of AOC 1044
Plasma pharmacokinetic (PK) parameters
Terminal half-life (T1/2) of AOC 1044
Plasma pharmacokinetic (PK) parameters
Area under the concentration-time curve (AUC) of AOC 1044
PMO44 levels in skeletal muscle tissue
Urine pharmacokinetic parameters
Fraction of PMO44 excreted in urine
Change from baseline in exon skipping as measured in skeletal muscle (Part B only)
Absolute change from baseline in dystrophin protein level in skeletal muscle (Part B only)
Percentage change from baseline in dystrophin protein level in skeletal muscle (Part B only)

Full Information

First Posted
December 6, 2022
Last Updated
September 27, 2023
Sponsor
Avidity Biosciences, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05670730
Brief Title
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
Acronym
EXPLORE44
Official Title
A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunteers and Participants With DMD Mutations Amenable to Exon 44 Skipping
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 9, 2022 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avidity Biosciences, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Duchenne Muscular Dystrophy, Exon 44
Keywords
EXPLORE44, Avidity Biosciences, Avidity, AOC 1044

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
AOC 1044-CS1 (EXPLORE44) is a 2-part study: Part A: 5 cohorts with single ascending doses conducted in healthy adult volunteers Part B: 3 cohorts with multiple ascending doses in participants with DMD mutations amenable to exon 44 skipping
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AOC 1044-CS1 Part A - Single Dose Levels 1-5
Arm Type
Experimental
Arm Description
AOC 1044 will be administered once.
Arm Title
AOC 1044-CS1 Part A - Single Dose: Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo will be administered once.
Arm Title
AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3
Arm Type
Experimental
Arm Description
AOC 1044 will be administered three times.
Arm Title
AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo will be administered three times.
Intervention Type
Drug
Intervention Name(s)
AOC 1044
Intervention Description
AOC 1044 will be administered via intravenous (IV) infusion
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline
Intervention Description
Placebo will be administered via intravenous (IV) infusion.
Primary Outcome Measure Information:
Title
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame
Through study completion, up to Day 85 (Part A) or Day 169 (Part B)
Secondary Outcome Measure Information:
Title
Plasma pharmacokinetic (PK) parameters
Description
Maximum plasma concentration (Cmax) of AOC 1044
Time Frame
Through Week 8 (Part A); Through Week 12 (Part B)
Title
Plasma pharmacokinetic (PK) parameters
Description
Terminal half-life (T1/2) of AOC 1044
Time Frame
Through Week 8 (Part A); Through Week 12 (Part B)
Title
Plasma pharmacokinetic (PK) parameters
Description
Area under the concentration-time curve (AUC) of AOC 1044
Time Frame
Through Week 8 (Part A); Through Week 12 (Part B)
Title
PMO44 levels in skeletal muscle tissue
Time Frame
Through Week 4 (Part A); Through Week 16 (Part B)
Title
Urine pharmacokinetic parameters
Description
Fraction of PMO44 excreted in urine
Time Frame
Day 1-2 (0-24 hours after first dose) (Part A); Day 1-2 (0-24 hours after first dose) (Part B)
Title
Change from baseline in exon skipping as measured in skeletal muscle (Part B only)
Time Frame
Baseline, Week 16
Title
Absolute change from baseline in dystrophin protein level in skeletal muscle (Part B only)
Time Frame
Baseline, Week 16
Title
Percentage change from baseline in dystrophin protein level in skeletal muscle (Part B only)
Time Frame
Baseline, Week 16

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Part A: Key Inclusion Criteria: Aged 18 to 55 years, inclusive, at the time of informed consent Body mass index (BMI) of 18.5 to 32.0 kg/m2 Key Exclusion Criteria: Clinically significant abnormalities in laboratory results, ECGs, or vitals Current or recent use of prescription or nonprescription drugs Positive drug/alcohol test at Screening or Day -1 Elevated blood pressure (BP) >130/80 mmHg at Screening Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply Part B: Key Inclusion Criteria: Aged 7 to 27 years, inclusive, at the time of informed consent Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years Confirmation of DMD gene mutation amenable to exon 44 skipping Weight ≥ 23 kg Ambulatory or non-ambulatory Ambulatory participants: LVEF ≥50% and FVC≥50% Non-ambulatory participants: LVEF ≥45% and FVC≥40% PUL 2.0 entry item A ≥3 If on corticosteroids, stable dose for 30 days before screening and throughout the study Key Exclusion Criteria: Biceps brachii muscles unsuitable for biopsy Serum hemoglobin < lower limit of normal Uncontrolled hypertension or diabetes Prior treatment with any cell or gene therapy Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent Recently treated with an investigational drug History of multiple drug allergies
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Avidity Biosciences, Inc.
Phone
858-771-7038
Email
medinfo@aviditybio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Stahl, MD, PhD
Organizational Affiliation
Avidity Biosciences, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rabia Farooquee
Facility Name
Rare Disease Research - Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda Almaras
Facility Name
Worldwide Clinical Trials (Part A only)
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78217
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

We'll reach out to this number within 24 hrs